VNDA — Vanda Pharmaceuticals Inc. catalysts
Next verified catalyst
2026-10-01 — Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Un · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10 (month) in 11d
ESTIMATED |
READOUT
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participan
Phase 2 · Hypertension, Uncontrolled Hypertension |
VNDA Vanda Pharmaceuticals Inc. | iloperidone |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|
| 2026-12 (month) in 2mo
ESTIMATED |
READOUT
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment
Phase 3 · Social Anxiety Disorder (SAD) |
VNDA Vanda Pharmaceuticals Inc. | VQW-765 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|
| 2026-12-01 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1
Phase 3 · Nausea and Vomiting, Obesity |
VNDA Vanda Pharmaceuticals Inc. | Tradipitant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|